Description
Since the human body cannot produce these and due to the fact that they are necessary for the human body to be able to undertake a range of functions, they must be derived through nutrition and/or consumed through supplements.
Selecting the very best possible sources in producing such a supplement is very important. In the case of Neuroaspis® PLP10, Omega-3 are extracted from wild-caught Tuna surpassing all IFOS-5 standards with high concentration of 1035 mg DHA per single teaspoon. The same mindset and dedication was utilized in selecting all the other ingredients of Neuroaspis® PLP10 as well. It also contains Omega-6 which come from the finest cold-pressed Borage Seed Oil, Vitamin E concentration in the form of both
Alpha-Delta and Gamma-Tocopherol.
Evidently, a number of research papers published demonstrate the positive effects Neuroaspis® PLP10 can have on patients’
outcomes.
In a randomised, doubleblind clinical trial; treatment with Neuroaspis® PLP10 significantly reduced the relapse rate and the risk of sustained disability progression without any reported serious adverse events in patients with Multiple Sclerosis (1). An additional study was published by Aristotelous et al., 2021, supporting the hypothesis that Neuroaspis® PLP10 can act protectively against functional deterioration of patients with a progressive disease such as
Relapsing-Remitting Multiple Sclerosis (3).
Another study by Stavrinou et al., 2020 demonstrated that a high-dose of specific omega-3 and omega-6 fatty acids supplementation, in combination with specific antioxidant vitamins, can possibly prevent or treat cognitive impairment and functional decline; therefore, improve independence and quality of life of older individuals with mild
cognitive impairment (2).
Furthermore, Neuroaspis® PLP10 was shown to improve the symptoms of Parkinson’s disease and possibly play a major role in
delaying the progression of the disease when used as an adjuvant to the conventional treatment (4).
In general, Neuroaspis® PLP10 can help support
- Brain & Memory
- Heart
- Joints & Bone
- Immune System
- Antioxidant & Skin
- Eye & Vision
1.Pantzaris MC, Loukaides GN, Ntzani EE, Patrikios IS. A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial. BMJ Open. 2013 Apr 17;3(4):e002170. doi: 10.1136/bmjopen-2012-002170. PMID: 23599375; PMCID: PMC3641495.
2. Stavrinou PS, Andreou E, Aphamis G, Pantzaris M, Ioannou M, Patrikios IS, Giannaki CD. The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment. Nutrients. 2020 Jan 26;12(2):325. doi: 10.3390/nu12020325. PMID: 31991898; PMCID: PMC7071310.
3. Aristotelous P, Stefanakis M, Pantzaris M, Pattichis CS, Calder PC, Patrikios IS, Sakkas GK, Giannaki CD. The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis. Nutrients. 2021 Oct 19;13(10):3661. doi: 10.3390/nu13103661. PMID: 34684661; PMCID: PMC8540949.
4.Pantzaris M, Loukaides G, Paraskevis D, Kostaki EG, Patrikios I. Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg. 2021 Nov;210:106954. doi: 10.1016/j.clineuro.2021.106954. Epub 2021 Sep 17. PMID: 34607196.
